This correlation suggests that the regulatory mechanism of BRD4 on KEAP1 and G6PD may be beyond SCLC and may exist in a variety of cancers which provides a new basis for overcoming drug resistance to BETis in other cancer types. Here, G6PD is linked to small cell lung carcinoma.